Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. director reports a large share purchase. A company director filed a Form 4 disclosing the acquisition of 400,000 Biohaven common shares on 11/13/2025 in an underwritten public offering at a price of $7.5 per share. Following this transaction, the director beneficially owns 2,020,071 common shares in total, held directly.
Biohaven Ltd. (BHVN) reported an insider purchase by a director who indirectly acquired 3,333,333 common shares on 11/13/2025. The transaction was coded "P" for a purchase at a price of $7.50 per share and is described as common shares acquired in an underwritten public offering.
After this transaction, indirect beneficial ownership includes 5,653,904 common shares held by the John W Childs 2013 Revocable Trust, as well as additional indirect holdings of 4,096,512, 76,570, 25,291 and 24,452 common shares through various charitable remainder trusts.
Biohaven Ltd. director and CEO Vlad Coric reported purchasing additional common shares of BHVN on 11/13/2025 in an underwritten public offering. Two trusts associated with his family each acquired 333,333 common shares at $7.50 per share, one held by The Vlad Coric Family Trust and the other by The Vladimir Coric Marital Trust.
After these transactions, reported holdings include 1,195,275 common shares held by The Vlad Coric Family Trust, 740,546 common shares held by The Vladimir Coric Marital Trust, and 109,565 common shares in a 401(k) plan. An additional 1,797,148 common shares are reported as held directly. The report notes that the family trust shares are for the benefit of family members, that his spouse is trustee, and that Coric disclaims beneficial ownership of those trust-held securities. It also states that the direct balance includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 30, 2025.
Biohaven Ltd. received a Schedule 13G from Janus Henderson Group plc reporting beneficial ownership of 6,772,113 shares of common stock, representing 6.4% of the class as of the event date 09/30/2025. The filer reports 0 sole voting and dispositive power and 6,772,113 shared voting and dispositive power.
The filing also states that JHIUS may be deemed the beneficial owner of 6,634,902 shares, or 6.3%, with shared voting and dispositive power and no sole power. The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Biohaven Ltd. (BHVN) completed a registered public offering of 26,833,334 common shares at $7.50 per share, including the full exercise of the underwriters’ option to purchase 3,500,000 additional shares. Gross proceeds to the company were approximately $200 million before underwriting discounts, commissions, and expenses.
The offering was underwritten by J.P. Morgan and Goldman Sachs and conducted under an effective shelf registration, using a base prospectus dated October 2, 2023 and a prospectus supplement dated November 12, 2025. The underwriting agreement includes customary representations, conditions, indemnification, and termination provisions.
Biohaven Ltd. (BHVN) is offering 23,333,334 common shares at $7.50 per share in a primary offering. The deal totals $175,000,005 before fees, with underwriting discounts of $0.45 per share. The company estimates net proceeds of approximately $164.0 million and plans to use the funds for general corporate purposes.
The underwriters have a 30‑day option to buy up to 3,500,000 additional shares. Common shares outstanding are expected to be 129,136,989 immediately after the offering, or 132,636,989 if the option is fully exercised. Certain insiders, including the CEO, have indicated interest in purchasing about $60,000,000 of shares, with $5,000,000 indicated by the CEO; these indications are not binding. A 30‑day lock‑up applies to the company and to directors and officers. BHVN trades on the NYSE; the last reported sale was $8.52 on November 11, 2025.
Biohaven Ltd. is conducting a $150,000,000 primary offering of common shares pursuant to a prospectus supplement. The deal includes a 30‑day option for underwriters to purchase additional shares after pricing.
The company expects to use net proceeds for general corporate purposes. Insider interest is indicated at approximately $60,000,000 in aggregate, including about $5,000,000 from the CEO, subject to allocation by underwriters. Biohaven’s common shares trade on the NYSE under “BHVN”; the last reported price was $7.79 on November 10, 2025.
As context, 105,803,655 common shares were outstanding as of September 30, 2025; this is a baseline figure, not the amount being offered. The company has a 30‑day lock‑up, and directors and officers are subject to similar lock‑ups, with customary exceptions described under “Underwriting.”
Biohaven Ltd. (BHVN) reported a larger quarterly loss and added new debt to fund its pipeline. For Q3 2025, net loss was $173.4 million compared with $160.3 million a year ago. Operating expenses were $169.4 million, with research and development at $141.2 million and general and administrative at $28.2 million. Net investment income was $3.4 million.
Liquidity shifted toward cash: cash and cash equivalents were $184.8 million and marketable securities were $75.4 million as of September 30, 2025. Year‑to‑date, operating cash outflows totaled $478.8 million, partly offset by $250.0 million of proceeds from senior secured notes issued in April 2025. Notes payable measured at fair value were $268.3 million at quarter‑end. A derivative liability related to a prior agreement declined to $22.0 million.
Shareholders’ equity moved to a deficit of $17.2 million, from $423.4 million at December 31, 2024, reflecting continued losses and fair value adjustments. The company stated it expects existing cash, cash equivalents, marketable securities, and equity purchase commitments to fund operations for at least one year after issuance of these financial statements. Common shares outstanding were 105,803,655 as of September 30, 2025.
Biohaven Ltd. (BHVN) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The company reported this event on November 10, 2025.
The information was provided under Item 2.02 and includes Exhibit 99.1 titled “Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments.” As noted under General Instruction B.2., the Item 2.02 information and Exhibit 99.1 are furnished, not filed.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership in Biohaven Ltd (BHVN). The filing states ownership of 2,875,190 shares, representing 2.71% of the company’s common stock as of 09/30/2025.
The filing details show sole voting power: 0 shares and shared voting power: 535,665 shares. Vanguard reports sole dispositive power: 2,228,799 shares and shared dispositive power: 646,391 shares. Vanguard is identified as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business, not to change or influence control. Vanguard notes its clients have rights to dividends or sale proceeds, and no other person’s interest exceeds 5%.